Monomethyl Fumarate
Blasts Under 5 Percent of Bone Marrow Nucleated Cells
Fred Hutchinson Cancer CenterSmall moleculePhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Blasts Under 5 Percent of Bone Marrow Nucleated Cells cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Fred Hutchinson Cancer Center | Phase 2 | BB |
CYCLOSPORIN A Fred Hutchinson Cancer Center | Phase 2 | B |
Cyclophosphamide Fred Hutchinson Cancer Center | Phase 2 | B |
Lipitor Fred Hutchinson Cancer Center | Phase 2 | B |
Treosulfan Fred Hutchinson Cancer Center | Phase 2 | B |
View all 11 →
Same molecule, other indications
Monomethyl Fumarate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →